Posts Tagged ‘number’

Platelet Rich Plasma (PRP) Treatment in Hyderabad India

Platelet Rich Plasma Injections | Posted by admin
Sep 02 2015

What isPlatelet Rich Plasma

Eternesse Anti Aging Clinicis the only clinic in India that currently offersPRPto its patients.Platelet Rich Plasma, orPRP, isblood plasma with concentrated plateletsand othergrowth factors. The concentrated platelets found inPRPcontain huge reservoirs ofbioactive proteins, includinggrowth factorsand signaling proteins that are vital to initiate and acceleratetissue repairandregeneration. These growth factors number at least a dozen different factors. Thesebioactive proteinsinitiate connective tissue healing in tissues such asmeniscus (knee)androtator cuff tissue, boneandarticular cartilage regenerationand repair, promote development of new blood vessels, and stimulate thewound healing process.

ThePRPsignals the body to send instem cellsto repair the area of injury.PRP injectionsare sometimes done under fluoroscopic guidance (living x-ray) atEternesse Anti Aging Clinic. This is done for precise localized delivery of these healing factors into injured ligaments, muscles, and joints.

Steps Involved in Platelet Rich Plasma Therapy

Platelet Rich Plasma therapyis a treatment option for variousorthopaedic injuriesand conditions, which have traditionally required surgery or other extensive treatments.PRP injectionsare being utilized inorthopaedicswith increasing frequency and effectiveness. Injuries currently being treated with thePRP therapyare arthritis of the hip, knee, shoulder, ankle and other joints.PRPalso is utilized for soft tissue injuries such astendonitis, muscle sprainsandtears,and various types ofligament injuries. These include common tendon injuries such astennis and golfers elbow,Achilles tendonitisandknee tendonitis. PRP is also used to treat various injuries and conditions affecting (joint) injuries. These include rotator cuff and meniscus injuries.

AlthoughPRPtechnology is consideredcutting edge technology, it was initially developed 20 years ago for heart surgery to aid with the wound healing and blood loss. Its benefits are now being applied towards the facilitating of healing muscle, tendons, ligaments, articular and meniscal injuries. In fact, PRP has been widely used in Europe for many years.

To preparePRP, a small amount of blood is taken from the patients arm. The blood is then placed in acentrifuge. The centrifuge spins and separates the platelets form the rest of the blood components. The entire process takes less than 15 minutes and increases the concentration of platelets and growth factors up to 600%. Using the patients own blood, specially prepared platelets are taken and re-injected into the affected area. These platelets release special growth factors that lead to tissue healing. By using theconcentrated platelets, we increase the growth factors up to eight times which promotes temporary relief and stops inflammation.PRP injectionsactually heal the area over a period of time. This can be anywhere from one to three months.

The human body has a remarkable ability to heal itself, and by re-injecting concentrated platelets, we are facilitating thenatural healing process. ThePRPinjections are calling instem cellsto repair the area. When performing these injections, we must do whatever we can to maximize stem cell release to optimize healing.

PRP is a non-surgical technique which would suggest it is more convenient than a surgery.

Platelets are one of the primary constituents of blood along with white blood cells, red blood cells and plasma.

Platelets in the blood are responsible for the release of growth factors-power proteins which help repair and regenerate soft tissues.

Using a special procedure, we can extract the platelets out of the blood and increase their concentration by 1000 %. When injected into the knee, these highly concentrated platelets aid in the speedy healing of the knee.

We know certain factors diminish stem cell release such as smoking and alcohol intake. Obviously avoiding these pitfalls will do nothing but increase the success of the procedure. The platelets work by causing an inflammatory reaction. If we somehow diminish this inflammatory reaction than we may significantly decrease the chances of having a good result. For this reason, the use of anti-inflammatory drugs such as Advil, Aleve, Motrin, ibuprophen etc. are not recommended. This restriction should be in place for about 4-6 weeks.

The use ofomega 3-fish oiland othernatural anti-inflammatory agentsdo not seem to work the same way as theNSAIDS(non-steroidal anti-inflammatories) and are thus not restricted.

What is the number of injections that are administered?

The number of injections performed depends upon the severity and the type of condition being treated. Age also seems to have an effect on the number of injections given. Typically, younger people generally need fewer injections for the same condition than a person who is older.

Is there any pain involved?

After the injection is given, there is usually a marked increase in pain for anywhere from 5-10 days. Tylenol and possibly a mild narcotic usually handle this pain. The pain may start up again only later to go away. A good analogy is that of a roller coaster where the initial few days are like the big drop on the roller coaster than the remaining few days are like smaller dips on a roller coaster!

We are Indias bestPRP Therapy provider. Dr. Leroy Rebello is Indias foremost expert and authority on Platelet Rich Plasma. If you are anorthopedist making aninquiry for your patient or someone suffering from bone injuries please contact us. If you simply want to rejuvenate your face and body using growth cells, then you are in good hands with the countrys best PRP specialist who will attend upon you. You can call us on the number below for an initial consultation with Dr. Rebello.

Continued here:
Platelet Rich Plasma (PRP) Treatment in Hyderabad India

Tags: , , , , , , , , , , , , ,
Comments Closed

Autism - Wu Medical Center - A Leading Medical Center for …

Stem Cell Medical Center | Posted by admin
Jun 11 2015

Stem Cell Therapy for AutismMay 25th, 2015

Like Wu, Xiaojuan Wang, Freda Peng, Bo Cheng, Susan Chu

Wu Medical Center

The patient is 8-year-old boy. He was presented with language, mental, behavioral and human communication disorders for the past 5 years. He was diagnosed as Autism. He was born full-term with normal delivery. He was hyperactive, upset, agitated, impaired language development and was unable to communicate with others when he was 2 years old.

Physical examination: he was stable, Skin and mucous membrane were with no yellow stain or petechia. His heart and lung were normal. He was alert, his comprehension, judgment, attention and adaptability were bad. He was hyperactive, upset, unquiet, soliloquize and he couldnt answer questions. He could count from 1-10. He couldnt cooperate with the memory, calculation ability, or orientation examinations. He seldom had eye contact with others. He couldnt cooperate with the cranial nerves, sensation and coordinated movement during examinations. The muscle power of four limbs was at level 5, his muscle tension was normal. The tendon reflex decreased. The pathological sign was negative. All of the laboratory examination and accessory examinations were normal. He was diagnosed as Autism.

Treatment target: increase the number of normal neural stem cells (NSCs) in the brain, switch on neural development, repair and regenerate the nerves. Increase the brain function, improve the patients cognitive function and communication skills.

Treatment procedure and results: We gave the patient 4 times neural stem cells (NSCs) and 4 times mesenchymal stem cells (MSCs) implantation treatment. The stem cells were activated in the patients body to repair the damaged nerves. Together with nourishment of the neurons, improve circulation, regulating the immune, daily rehabilitation training was incorporated. After the treatment, the patient was stable, developed a good spirit and mood. He seldom gets upset and he developed more concentration. He could see movies or listen to music by himself, and the duration was increased to between 30-40 minutes than before. He speaks more with family members. He could answer questions and gained more vocabulary. He could say a sentence which is made up of 6 words. His learning skill was better. The memory, calculation ability, orientation, comprehension and attention were better. He had more eye contact with others. His nerves, sensation, coordinated movement examinations and meningeal irritation sign examination cooperation degree was better.

Case analysis: Autism is also called autistic disorder, it is one subtype of the catholicity eccyliosis. Male patients were more than female as observed. This disease onset at early infancy. The cardinal symptoms: various degrees of speech disturbance, human communication disorders, less interesting or mechanic behavior. Around 3/4 young patients accompanied with visible mental retardation. The main pathogen was unclear, it may be: heredity, perinatal period factors, abnormal immune system or imbalance of various neuroendocrine and neurotransmitter function. The patient had this disease from very young, the pathogen was unclear, and his symptoms were: abnormal mind and behaviors, cognitive disorder, bad communication skills and excitement.

There are a lot of methods to treat autism, but most of them lack medical evidences and there is no best treatment plan. Our center uses advanced NSCs transplantation technique to treats patients with autism. The NSCs is used together with MSCs to make the imbedded NSCs increase the number of brain and spinal cord nerve cells, promotes nerve differentiation and growth to improve his cognition and mental. This technique was used in this patient and he recovered well and not only his cognition and mental, his self-care ability and social skills were improved also. This provided relief of mental stress and daily burden to his relatives. This brings hope to patients with this disease.

Research under our direction, the treatment result was satisfactory. During retrospective experiment on animals, we found the same program had made great advances in nerve precursor cells structure, migration, cortical tissue, neuron differentiation and connection. For example: a small group of neurons migration lag in specific area or appear in ectopia area of the patient, could result in mental hypoevolutism, epilepsy or speech impediment. This can be fixed with implantation of nerve precursor cell. The shape and structure of cortex can be normal. The safety of this treatment was confirmed in many medical literatures. But each patient need complicated clinical technology supporting, because the brain was controlled by gene in the development process, for example: when we use the NSCs to correct neuron developmental deviation and abnormality, neuron development need growth factors participation. It also need immunological surveillance. Over growth nerve will be controlled by immune system, only in that way can we get good result. All the processes need to be controlled by experienced clinician and complicated clinical technology.

Follow this link:
Autism – Wu Medical Center – A Leading Medical Center for …

Tags: , , , , , , , ,
Comments Closed

'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows

Cell Medicine | Posted by admin
Jan 02 2015

Released: 30-Dec-2014 1:50 PM EST Embargo expired: 1-Jan-2015 2:00 PM EST Source Newsroom: Johns Hopkins Medicine Contact Information

Available for logged-in reporters only

Newswise Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide. By their measure, two-thirds of adult cancer incidence across tissues can be explained primarily by bad luck, when these random mutations occur in genes that can drive cancer growth, while the remaining third are due to environmental factors and inherited genes.

All cancers are caused by a combination of bad luck, the environment and heredity, and weve created a model that may help quantify how much of these three factors contribute to cancer development, says Bert Vogelstein, M.D., the Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.

Cancer-free longevity in people exposed to cancer-causing agents, such as tobacco, is often attributed to their good genes, but the truth is that most of them simply had good luck, adds Vogelstein, who cautions that poor lifestyles can add to the bad luck factor in the development of cancer.

The implications of their model range from altering public perception about cancer risk factors to the funding of cancer research, they say. If two-thirds of cancer incidence across tissues is explained by random DNA mutations that occur when stem cells divide, then changing our lifestyle and habits will be a huge help in preventing certain cancers, but this may not be as effective for a variety of others, says biomathematician Cristian Tomasetti, Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. We should focus more resources on finding ways to detect such cancers at early, curable stages, he adds.

In a report on the statistical findings, published Jan. 2 in Science, Tomasetti and Vogelstein say they came to their conclusions by searching the scientific literature for information on the cumulative total number of divisions of stem cells among 31 tissue types during an average individuals lifetime. Stem cells self-renew, thus repopulating cells that die off in a specific organ.

It was well-known, Vogelstein notes, that cancer arises when tissue-specific stem cells make random mistakes, or mutations, when one chemical letter in DNA is incorrectly swapped for another during the replication process in cell division. The more these mutations accumulate, the higher the risk that cells will grow unchecked, a hallmark of cancer. The actual contribution of these random mistakes to cancer incidence, in comparison to the contribution of hereditary or environmental factors, was not previously known, says Vogelstein.

To sort out the role of such random mutations in cancer risk, the Johns Hopkins scientists charted the number of stem cell divisions in 31 tissues and compared these rates with the lifetime risks of cancer in the same tissues among Americans. From this so-called data scatterplot, Tomasetti and Vogelstein determined the correlation between the total number of stem cell divisions and cancer risk to be 0.804. Mathematically, the closer this value is to one, the more stem cell divisions and cancer risk are correlated.

Our study shows, in general, that a change in the number of stem cell divisions in a tissue type is highly correlated with a change in the incidence of cancer in that same tissue, says Vogelstein. One example, he says, is in colon tissue, which undergoes four times more stem cell divisions than small intestine tissue in humans. Likewise, colon cancer is much more prevalent than small intestinal cancer.

More here:
'Bad Luck' of Random Mutations Plays Predominant Role in Cancer, Study Shows

Tags: , , , , , , , ,
Comments Closed

New molecule allows for up to 10-fold increase in stem cell transplants

Stem Cell Treatment | Posted by admin
Sep 20 2014

Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the journal Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.

Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, the research has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.

A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.

According to Dr. Guy Sauvageau, “This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer.”

The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.

“These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories,” adds Dr. Guy Sauvageau. “Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRIC’s medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule.”

Context

Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.

Furthermore, it is not necessary for the immunological compatibility between donor and recipient to be perfect, unlike in a bone marrow transplant. However, in most cases the number of stem cells obtained from an umbilical cord is much too low for treating an adult, and its use is confined above all to the treatment of children. With the new molecule UM171 it will be possible to multiply stem cells in culture and to produce enough of them to treat adults, especially those who are not Caucasian, and who because of the lack of donors have limited access to transplants.

Collaborators from the Maisonneuve-Rosemont Hospital, the British Columbia Cancer Agency, the Ontario Cancer Institute and the Fred Hutchison Cancer Research Center also played an important role in evaluating the biological properties of this new molecule, and those from the University of Toronto in developing the bioreactor.

Continue reading here:
New molecule allows for up to 10-fold increase in stem cell transplants

Tags: , , , , , , ,
Comments Closed

Growing Stem Cells in Space: Medicine's Next Big Thing?

Stem Cell Clinic | Posted by admin
Jun 22 2014

FRESNO, Calif. (KFSN) —

It’s something Jon Galvan experienced five years ago after he almost died from a hemorrhagic stroke while atSubmit work.

“I was typing away and I felt a pop in my head,” Galvan told Ivanhoe.

He was able to recover, but Abba Zubair, MD, PhD, Medical Director of Transfusion Medicine and Stem Cell Therapy at Mayo Clinic, Florida says not everyone is as fortunate.

“If it happens, you either recover completely or die,” Dr. Zubair told Ivanhoe. “That’s what killed my mother.”

SubmitDr. Zubair wants to send bone marrow derived stem cells to the international space station.

“Based on our experience with bone marrow transplant you need about 200 to 500 million cells,” Dr. Zubair said.

But conventionally grown stem cells take a month. Experiments on earth have shown that stem cells will grow faster in less gravity.

“Five to ten times faster, but it could be more,” Dr. Zubair said.

Specifically he hopes to expand the number of stem cells that will help regeneration of neurons and blood vessels in hemorrhagic stroke patients.

Link:
Growing Stem Cells in Space: Medicine's Next Big Thing?

Tags: , , , , , , , , , , ,
Comments Closed

Stem Therapy May Improve Survival of Heart Patients

Stem Cell Treatment | Posted by admin
May 03 2014

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group’s report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

Read more:
Stem Therapy May Improve Survival of Heart Patients

Tags: , , , , , , , , , , , , ,
Comments Closed

Diabetes Treatment at EmCell - Video

Stem Cell Treatment | Posted by admin
Apr 02 2014



Diabetes Treatment at EmCell
At present, more than 200 million people around the world are affected with diabetes, and this number is growing year after year. Among various types of ther…

By: Stem Cell Therapy Center EMCELL

View post:
Diabetes Treatment at EmCell – Video

Tags: , , , , , , , , , , , , , ,
Comments Closed

Stell Cell Research – Stem Cell Cafe

Stell Cell Research | Posted by admin
Dec 01 2013

Here at Macleans, we appreciate the written word. And we appreciate you, the reader. We are always looking for ways to create a better user experience for you and wanted to try out a new functionality that provides you with a reading experience in which the words and fonts take centre stage. We believe youll appreciate the clean, white layout as you read our feature articles. But we dont want to force it on you and its completely optional. Click View in Clean Reading Mode on any article if you want to try it out. Once there, you can click Go back to regular view at the top or bottom of the article to return to the regular layout. Scientist Dr. Mark Post poses with samples of in-vitro meat in a laboratory, at the University of Maastricht in the Netherlands on November 9, 2011. (Francois Lenoir/Reuters) Its high time for summer barbecue season. On Aug. 5, as long weekend revelers across Canada throw steaks and sausages on the grill, Dr. Mark Post will be cooking up something very different: a hamburger made of animal stem cells, grown in his lab at Maastricht University in the Netherlands. This one little five-ounce patty has taken him years to perfect, at a cost of 300,000 euros, or over $409,500 (donated by an anonymous investor), making it what must be the most expensive and labour-intensive sandwich patty in history. Some doubted it could be done. As the burger is unveiled in Londonthen bitten, chewed, swallowed and consumed, for all the world to seePosts burger will redefine meat as we know it. This is the food of the future. Post, a medical doctor, has been attempting to create tissues in the lab for almost a decade. The applications are huge: engineered human tissues could be used to test drugs, for example, or to treat many diseases where the body wastes away. To Post, the food application started out as an interesting side project, one that soon stole the spotlight from his other work. Meat for consumption is in theory, much easier to grow, he told Macleans in an interview in 2012. The tissue does not need to physically integrate into the body. I considered it a closer goal to reach, he says, and a very important one. Indeed, the global appetite for meat is growing. Livestock production already takes up 30 per cent of the land surface on our planet, says a 2006 United Nations report, producing more greenhouse gas emissions than all our cars and trucks, combined. According to Patrick O. Brown of Stanford University, eating one four-ounce hamburger is the equivalent of leaving a bathroom faucet running round-the-clock for a week. Developing nations are increasingly emulating the meat-heavy Western diet, and it isnt sustainable. We are heading towards a meat shortage worldwide, Post says. Instead of producing beef, pork and poultry on massive industrial farms, in the near future, he predicts, well be growing it in factories. And while this first hamburger was incredibly expensive to make, as techniques are perfected and lab-grown stem-cell burgers can be mass-produced, the cost will go down; one day it could be lower than the price of traditionally raised meat, which is expected to rise. Of course, growing a minced hamburger pattylet alone a dense, fat-marbled steakisnt a simple task. Post and his team harvested stem cells from a cows muscle tissue, and bathed them in a special formula of nutrients. As these cells start to differentiate into muscle cells, theyre hooked to attachment points (Post has used Velcro) to create tiny strips of tissue, like a tendon. Eventually, they start to contract on their own. The downside for animal lovers is that you still need animals, a donor herd to provide stem cells, Post says. But compared to factory farming today, the number would be very small. If we grew all our meat in a lab, Post believes, the number of livestock worldwide could be reduced by a factor of one millionthe equivalent of reducing 10 billion livestock animals on the planet to 10,000. This would free up land, water, and other resources, while making sure remaining livestock didnt suffer a death fraught with the issues of large-scale slaughter. Other than Post, only a handful of scientists are working on lab-grown meat; others believe the future lies in plant-based substitutes, ones so good they could fool even the most discerning palate, although Post maintains that we humans will always have an appetite for the real thing. Worldwide, the meat-eater population is going to grow. Theres no doubt about that, he says. Posts hamburger is a powerful proof of concept, an important first step. As we begin to unravel the implications of this one burgerfor science, for health care, and for the food supply that feeds everyone on the planetwell be watching on Aug. 5, with bated breath, wondering what, exactly, it tastes like. Anyone who wants to follow along can watch a livestream of the burger consumption on Aug. 5 atculturedbeef.net. Continued here: One lab-grown hamburger, coming up Blog Central, Kate Lunau

Original post:
Stell Cell Research – Stem Cell Cafe

Tags: , , , , , , , , , , , , , ,
Comments Closed

Canadian stem cell technology expected to offer new options for blood stem cell transplants

Stem Cell Treatment | Posted by admin
Sep 26 2013

Peter Zandstra receives the 2013 Till & McCulloch Award

OTTAWA, Sept. 25, 2013 /CNW/ – A Canadian technology that has the potential to boost the number of stem cells given to patients undergoing transplants of the blood-forming system has been recognized as the most impactful stem cell research paper authored by a Canadian in the past year. Dr. Peter Zandstra has been given the 2013 Till & McCulloch Award in recognition of this contribution to global stem cell research. Dr. Zandstra will accept the award and present a lecture entitled “Engineering pluripotent stem cell derived microtissues” as part of the Till & McCulloch Meetings, Canada’s premier stem cell event.

Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network, who launched the Till & McCulloch Award in 2005 and will make the award presentation, says the Zandstra group’s publication was chosen due to the impact their technology is expected to have. “This technology will hasten the promise of regenerative medicine and the therapeutic possibilities of umbilical cord blood and hematopoietic stem cells in particular. It is very likely that Fed-Batch technology will improve the outcome of blood system transplants for many patients. We are proud to award the 2013 lecture to Dr. Zandstra for his pioneering work.”

First author Elizabeth Csaszar, Zandstra and his team have developed a new culture system that has the ability to dramatically expand the clinical applications of hematopoietic (blood) stem cells (HSCs). Their breakthrough discovery is based on a Fed-Batch bioreactor technology and has the potential to improve the viability and success of cord blood stem cell transplantation by allowing for better-matched donors and increasing the number of stem cells in a transplant unit.

This new system will accelerate the possibilities of using HSC transplantation in clinical settings, especially in the treatment of certain forms of leukemia. The success rate of blood system transplantation is strongly correlated to the number of cells used. Dr. Zandstra’s Fed-Batch technology can produce over 11 times more HSCs than originally existed and is designed to be adaptively scaled-up for human transplantations in clinical settings.

The article for which the award was granted, published in the February 2012 issue of Cell Stem Cell, entitled “Rapid Expansion of Human Hematopoietic Stem Cells by Automated Control of Inhibitory Feedback Signaling,” explains this novel discovery to expand cord blood cells. Dr. Zandstra is a professor at the University of Toronto’sInstitute for Biomaterials & Biomedical Engineering, a principal investigator with the McEwen Centre for Regenerative Medicine and the Chief Scientific Officer at the Centre for Commercialization of Regenerative Medicine.

Dr. Zandstra, the Canadian Research Chair in Stem Cell Bioengineering, was very pleased to learn he had been chosen for this honour. “When I was told I would be receiving the 2013 lecture award, I was very honoured to be recognized in this way by the scientific community. I am thrilled to be in the same company as the previous winners, who are all exceptional researchers in our field and help to drive advances in health care that will improve the lives of many. This technology, and others being supported and developed through the Stem Cell Network, the Leukemia and Lymphoma Society and CCRM funding, represents an exciting opportunity for Canadian leadership in the clinically important area of cell transplantation to treat leukemia.”

Excerpt from:
Canadian stem cell technology expected to offer new options for blood stem cell transplants

Tags: , , , , , , , ,
Comments Closed

Grafix® Demonstrates Overwhelming Efficacy in Landmark Stem Cell Study for the Treatment of Diabetic Foot Ulcers

Stem Cell Treatment | Posted by admin
Aug 13 2013

COLUMBIA, Md.–(BUSINESS WIRE)–

Osiris Therapeutics, Inc. (OSIR), reported today that its multi-center, randomized, controlled clinical trial comparing the safety and effectiveness of Grafix to standard of care in patients with chronic diabetic foot ulcers had met the pre-specified stopping rules for overwhelming efficacy as determined by the data monitoring committee during a planned interim analysis. For the primary endpoint, 62% of patients receiving Grafix had complete wound closure compared to only 21% (p

The trial also reached statistical significance in favor of Grafix on all top-line secondary endpoints, demonstrating faster wound closure and a reduction in the number of treatments needed to achieve wound closure. In the crossover phase of the trial, patients whose wounds failed to close after 12 weeks of standard of care had an 80% closure rate when switched to Grafix. Importantly, patients randomized to receive standard of care were 74% more likely to experience an adverse event than those receiving Grafix (p=0.008). As a result, the blinded phase of the trial is being discontinued immediately and all patients randomized to the control arm will be offered treatment with Grafix.

Today, Osiris has established a new standard in diabetic wound care and has demonstrated to the world the tremendous impact stem cell products can have in medicine, said C. Randal Mills, Ph.D., Chief Executive Officer. Diabetic foot ulcers afflict 25% of all diabetics and are responsible for more hospitalizations than any other diabetic complication. With 25 million diabetics in the United States, the cost to our health care system is enormous. Through this rigorous study we have shown that Grafix can heal more patients, in less time, and with fewer complications.

Top-Line Data from the Interim Analysis of Protocol 302

(n=50)

(n=47)

These data are very compelling as we have not had a new cellular therapy for diabetic foot ulcers in over 10 years, said Dr. Larry Lavery, Principal Investigator and Professor of Plastic Surgery, University of Texas Southwestern Medical Center. Compared to other similarly designed studies, this trial demonstrates, by far, the largest relative improvement in complete wound closure. This is great news for our patients with diabetic foot ulcers that are at such high risk of losing their legs.

Grafix is a human cellular repair matrix that provides a high-quality source of living mesenchymal stem cells (MSCs). It is a flexible, conforming membrane that is applied directly to acute and chronic wounds.

We know now that an unfortunate consequence of diabetes is the pathological change that occurs with the number and functionality of certain stem cell populations necessary for optimal wound repair, said Michelle LeRoux Williams, Ph.D., Chief Scientific Officer. With Grafix, we are able to help correct this problem by providing patients with a rich source of healthy, non-controversial stem cells contained within a biologic matrix for easy delivery in the out-patient setting.

Read more from the original source:
Grafix® Demonstrates Overwhelming Efficacy in Landmark Stem Cell Study for the Treatment of Diabetic Foot Ulcers

Tags: , , , , , , , ,
Comments Closed